schliessen

Filtern

 

Bibliotheken

A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma

Safety and efficacy of pegylated liposome encapsulated doxorubicin (PL‐DOX) was compared with free doxorubicin as an adjuvant monotherapy in dogs with splenic haemangiosarcoma after splenectomy in a randomized prospective clinical trial. A total of 17 dogs in each group were treated. No significant... Full description

Journal Title: Veterinary and Comparative Oncology December 2011, Vol.9(4), pp.283-289
Main Author: Teske, E.
Other Authors: Rutteman, G. R. , Kirpenstein, J. , Hirschberger, J.
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: ISSN: 1476-5810 ; E-ISSN: 1476-5829 ; DOI: 10.1111/j.1476-5829.2011.00266.x
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: wj10.1111/j.1476-5829.2011.00266.x
title: A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma
format: Article
creator:
  • Teske, E.
  • Rutteman, G. R.
  • Kirpenstein, J.
  • Hirschberger, J.
subjects:
  • Canine
  • Doxorubicin
  • Haemangiosarcoma
  • Liposome
  • Spleen
  • Toxicity
ispartof: Veterinary and Comparative Oncology, December 2011, Vol.9(4), pp.283-289
description: Safety and efficacy of pegylated liposome encapsulated doxorubicin (PL‐DOX) was compared with free doxorubicin as an adjuvant monotherapy in dogs with splenic haemangiosarcoma after splenectomy in a randomized prospective clinical trial. A total of 17 dogs in each group were treated. No significant difference in survival between the two treatments was found. The calculated median overall survival time for the 34 dogs was 166 days [95% confidence interval (CI) 148–184]. The ½ year and one‐year survival was 41.2% (95% CI 24.8–56.9) and 22.7% (95% CI 9.9–37.4), respectively. In dogs treated with PL‐DOX, a desquamating dermatitis like palmar‐plantar erythrodysesthesia (PPES) was seen in two dogs, while three other dogs showed anaphylactic reactions. Cardiotoxicity was not seen in either treatment groups.
language:
source:
identifier: ISSN: 1476-5810 ; E-ISSN: 1476-5829 ; DOI: 10.1111/j.1476-5829.2011.00266.x
fulltext: fulltext
issn:
  • 1476-5810
  • 14765810
  • 1476-5829
  • 14765829
url: Link


@attributes
ID1336186338
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1111/j.1476-5829.2011.00266.x
sourceidwj
recordidTN_wj10.1111/j.1476-5829.2011.00266.x
sourcesystemOther
pqid904009808
galeid272251324
display
typearticle
titleA randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma
creatorTeske, E. ; Rutteman, G. R. ; Kirpenstein, J. ; Hirschberger, J.
ispartofVeterinary and Comparative Oncology, December 2011, Vol.9(4), pp.283-289
identifier
subjectCanine ; Doxorubicin ; Haemangiosarcoma ; Liposome ; Spleen ; Toxicity
descriptionSafety and efficacy of pegylated liposome encapsulated doxorubicin (PL‐DOX) was compared with free doxorubicin as an adjuvant monotherapy in dogs with splenic haemangiosarcoma after splenectomy in a randomized prospective clinical trial. A total of 17 dogs in each group were treated. No significant difference in survival between the two treatments was found. The calculated median overall survival time for the 34 dogs was 166 days [95% confidence interval (CI) 148–184]. The ½ year and one‐year survival was 41.2% (95% CI 24.8–56.9) and 22.7% (95% CI 9.9–37.4), respectively. In dogs treated with PL‐DOX, a desquamating dermatitis like palmar‐plantar erythrodysesthesia (PPES) was seen in two dogs, while three other dogs showed anaphylactic reactions. Cardiotoxicity was not seen in either treatment groups.
source
version8
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Teske, E.
1Rutteman, G. R.
2Kirpenstein, J.
3Hirschberger, J.
titleA randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma
descriptionSafety and efficacy of pegylated liposome encapsulated doxorubicin (PL‐DOX) was compared with free doxorubicin as an adjuvant monotherapy in dogs with splenic haemangiosarcoma after splenectomy in a randomized prospective clinical trial. A total of 17 dogs in each group were treated. No significant difference in survival between the two treatments was found. The calculated median overall survival time for the 34 dogs was 166 days [95% confidence interval (CI) 148–184]. The ½ year and one‐year survival was 41.2% (95% CI 24.8–56.9) and 22.7% (95% CI 9.9–37.4), respectively. In dogs treated with PL‐DOX, a desquamating dermatitis like palmar‐plantar erythrodysesthesia (PPES) was seen in two dogs, while three other dogs showed anaphylactic reactions. Cardiotoxicity was not seen in either treatment groups.
subject
0Canine
1Doxorubicin
2Haemangiosarcoma
3Liposome
4Spleen
5Toxicity
general
0Blackwell Publishing Ltd
110.1111/j.1476-5829.2011.00266.x
2Wiley Online Library
sourceidwj
recordidwj10.1111/j.1476-5829.2011.00266.x
issn
01476-5810
114765810
21476-5829
314765829
rsrctypearticle
creationdate2011
addtitleVeterinary and Comparative Oncology
searchscope
0wj
1wiley
scope
0wj
1wiley
lsr30VSR-Enriched:[pages, pqid, galeid]
sort
titleA randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma
authorTeske, E. ; Rutteman, G. R. ; Kirpenstein, J. ; Hirschberger, J.
creationdate20111200
facets
frbrgroupid6314473071684994382
frbrtype5
creationdate2011
topic
0Canine
1Doxorubicin
2Haemangiosarcoma
3Liposome
4Spleen
5Toxicity
collectionWiley Online Library
prefilterarticles
rsrctypearticles
creatorcontrib
0Teske, E.
1Rutteman, G. R.
2Kirpenstein, J.
3Hirschberger, J.
jtitleVeterinary and Comparative Oncology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Teske
1Rutteman
2Kirpenstein
3Hirschberger
aufirst
0E.
1G. R.
2J.
au
0Teske, E.
1Rutteman, G. R.
2Kirpenstein, J.
3Hirschberger, J.
atitleA randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma
jtitleVeterinary and Comparative Oncology
risdate201112
volume9
issue4
spage283
epage289
issn1476-5810
eissn1476-5829
genrearticle
ristypeJOUR
abstractSafety and efficacy of pegylated liposome encapsulated doxorubicin (PL‐DOX) was compared with free doxorubicin as an adjuvant monotherapy in dogs with splenic haemangiosarcoma after splenectomy in a randomized prospective clinical trial. A total of 17 dogs in each group were treated. No significant difference in survival between the two treatments was found. The calculated median overall survival time for the 34 dogs was 166 days [95% confidence interval (CI) 148–184]. The ½ year and one‐year survival was 41.2% (95% CI 24.8–56.9) and 22.7% (95% CI 9.9–37.4), respectively. In dogs treated with PL‐DOX, a desquamating dermatitis like palmar‐plantar erythrodysesthesia (PPES) was seen in two dogs, while three other dogs showed anaphylactic reactions. Cardiotoxicity was not seen in either treatment groups.
copOxford, UK
pubBlackwell Publishing Ltd
doi10.1111/j.1476-5829.2011.00266.x
pages283-289
date2011-12